Clinical Trial

Clinical Study to Evaluate the Efficacy and Safety of HH-006 in Patients With Chronic Hepatitis B Virus Infection

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Study HH006-202 is designed to assesses the efficacy and safety of HH-006 in adults chronic HBV infection. Eligible participants will receive study treatment for 48 weeks. All treated patients will also undergo a follow-up period after last study drug treatment.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-16
Trial Details
NCT Number NCT07519330
Lead Sponsor Huahui Health
Conditions Chronic Hepatitis B Virus Infection
Enrollment 45 participants
Start Date 2026-05-14
Primary Completion 2028-02-28 (estimated)
Study Completion 2028-03-22 (estimated)
Updated on ClinicalTrials.gov 2026-06-15